Project Grant HT94252510700
Award Date
8/1/25
Completion Date
7/31/27
Dollars Obligated
$174K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Buffalo, NY 14203, USA
Similar Awards
This federal Project Grant award of $708,000.00 provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research conducted by the Sloan-Kettering Institute for Cancer Research, a non-profit organization located in New York, NY. The research project is focused on investigating the "Prevalence and Biologic Impact of FGFR3 Genomic Alterations in Bladder Cancer". The 2-year award period runs from September 15, 2023 to...
This $260,250 Project Grant awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) will fund research by Health Research, Inc. on the role of the SLC45A3-ELK4 chimera as a molecular determinant of prostate cancer health disparity. The research, to be conducted from March 2025 to March 2027, aims to advance scientific understanding of the genetic and molecular mechanisms underlying disparities in prostate cancer outcomes. As a leading...
The U.S. Defense Health Agency awarded a $1,513,169 Project Grant to Health Research, Inc. to support the "LEVERAGING POLYAMINE METABOLISM TO TARGET EPIGENOMIC ADAPTABILITY AND LINEAGE PLASTICITY IN PROSTATE CANCER" research project under the Military Medical Research and Development program (CFDA 12.420). This 3-year grant, beginning on April 1, 2024, aims to develop innovative approaches for treating prostate cancer by targeting tumor metabolism and epigenetic mechanisms. As a...
This $1,301,250 Project Grant award from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program supports research by Health Research, Inc. to investigate methods for inhibiting myeloid-derived suppressor cell (MDSC) biogenesis to enhance the efficacy of immunotherapy in triple-negative breast cancer. The award, effective from March 1, 2025 to February 29, 2028, will fund advanced biomedical research to explore innovative approaches for transforming...
This federal Project Grant award, valued at $644,000.00 and issued by the Defense Health Agency, is funding research under the Military Medical Research and Development program (CFDA 12.420) at the University of California, Davis. The goal of the project is to develop a targeted nano-conjugate therapy for bladder cancer. Specifically, the researchers at UC Davis will be working to create an ultra-small DM1 nanoconjugate that can effectively target and treat bladder cancer. The award duration...
This federal Project Grant award of $654,090.00 from the Defense Health Agency is for the "CANCER CELL INTRINSIC REGULATION OF ANTIBODY-DRUG CONJUGATE TARGETS IN BLADDER CANCER" research project at Pennsylvania State University's Milton S. Hershey Medical Center. The research, which runs from September 30, 2024 to September 29, 2026, is funded under the Military Medical Research and Development (CFDA 12.420) program. The project aims to investigate innovative approaches to cancer...
The U.S. Department of Defense's Defense Health Agency awarded Health Research, Inc. a $1,545,300 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to conduct research on "TARGETING MYCAF-DRIVEN CASTRATION-RESISTANT PROSTATE TUMOR GROWTH." The award, which has a performance period of May 1, 2024 to April 30, 2027, will enable Health Research, Inc.'s Roswell Park Division to perform biomedical research and provide scientific services to advance...
This federal Project Grant award, valued at $1,339,689.00 and provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research to identify and characterize metastasis-driving tumor cell subpopulations in localized stage III clear cell renal cell carcinoma. The grant recipient, The Feinstein Institutes for Medical Research, will conduct this advanced biomedical and translational research over a 4-year period from August 1, 2024...
This Project Grant award from the U.S. Department of Defense's Military Medical Research and Development program (CFDA 12.420) provides $1,561,500.00 to Health Research, Inc. at Roswell Park Cancer Center to conduct research targeting prostate cancer metabolic vulnerabilities in the bone microenvironment. The goal is to develop new approaches to circumvent lethal metastatic disease. The 3-year award period runs from September 15, 2023 to September 14, 2026. As a non-profit research organization,...
The Defense Health Agency awarded a $1,561,500 Project Grant to Health Research, Inc. Roswell Park Division for the period of March 15, 2023 through March 14, 2026. The grant will support research into slow-cycling prostate cancer cells in therapy resistance, disease relapse, and metastasis. This award is being made under the Military Medical Research and Development program (CFDA 12.420). This program aims to transform military and public health through innovative medical research solutions for...